Liquidity and capital resources	3 Months Ended
Mar. 31, 2024
Liquidity And Capital Resources
Liquidity and capital resources	Note 2. Liquidity and capital resources As of March 31, 2024, the Company had cash of approximately $3.3 million. The Company used approximately $1.9 million of cash in operations during the three months ended March 31, 2024 and had stockholders’ equity as of March 31, 2024 and December 31, 2023 of approximately $3.0 million and $3.4 million, respectively. TELOMIR PHARMACEUTICALS, INC. NOTES TO CONDENSED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023 (Unaudited) Historically, the Company has been primarily engaged in developing TELOMIR-1. During these activities, the Company sustained substantial losses. The Company’s ability to fund ongoing operations and future clinical trials required for FDA approval is dependent on the Company’s ability to obtain significant additional external funding in the near term. Since inception, the Company has financed its operations through related party financings-see Note 5 and an initial public offering – see Note 7. Additional sources of financing may be sought by the Company. However, there can be no assurance that any fundraising will be achieved on commercially reasonable terms, if at all. As of the date of filing, the Company will continue to generate losses and have insufficient cash and cash equivalents on hand to support its operations for at least the 12 months following the date the financial statements are issued. These conditions raise substantial doubt about the Company’s ability to continue as a going concern through 12 months after the date the financial statements are issued.

Liquidity and capital resources

3 Months Ended

Mar. 31, 2024

Note 2. Liquidity and capital resources

As of March 31, 2024, the Company had cash of approximately $3.3 million. The Company used approximately $1.9 million of cash in operations during the three months ended March 31, 2024 and had stockholders’ equity as of March 31, 2024 and December 31, 2023 of approximately $3.0 million and $3.4 million, respectively.

TELOMIR PHARMACEUTICALS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023

(Unaudited)

Historically, the Company has been primarily engaged in developing TELOMIR-1. During these activities, the Company sustained substantial losses. The Company’s ability to fund ongoing operations and future clinical trials required for FDA approval is dependent on the Company’s ability to obtain significant additional external funding in the near term. Since inception, the Company has financed its operations through related party financings-see Note 5 and an initial public offering – see Note 7. Additional sources of financing may be sought by the Company. However, there can be no assurance that any fundraising will be achieved on commercially reasonable terms, if at all.

As of the date of filing, the Company will continue to generate losses and have insufficient cash and cash equivalents on hand to support its operations for at least the 12 months following the date the financial statements are issued. These conditions raise substantial doubt about the Company’s ability to continue as a going concern through 12 months after the date the financial statements are issued.